For about ten years we have annually arranged Biotech Umeå Investment Day, as a part of Västerbottensdagarna på Grand. Its a day full of partnering between life science startups from the Västerbotten region and international investors. Each partnering session is 25 minutes.
Around 30 investors and 30 entrepreneurs usually participate in Biotech Umeå Investment Day. The day ends with the Västerbotten buffet at Grand Hôtel’s Veranda.
The latest Biotech Umeå Investment Day was held on January 30, 2020, at Grand Hôtel.
If you have any questions, please contact Pia Keyser, firstname.lastname@example.org, 073-620 51 61.
Participating companies were:
At present, the following companies have registered to participate. More non-confidential information about the companies will be presented at this page during December 2019. In the middle of January, you will receive a link to select what companies you would like to meet during the partnering sessions.
Acne Treatment Project
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 700 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development. Read more about Acne Treatment Project in their onepager.
This company’s goal is to increase survival, improve quality of life and less suffering for cancer patients. Their novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer-induced cachexia and suppression of the immune system. Read more about Betulaceae Pharmaceutical in their onepager.
Brain Stimulation RehAtt® is a new concept for stroke-rehabilitation. A unique, effective rehabilitation product that combines neuroscience and cutting-edge technology to create an enriched, motivating training environment that stimulates brain plasticity and improves attention function by strengthening neuronal traffic. Proven effective even years after the stroke. Read more about Brain Stimulation in their onepager.
G4 cancer cure
Breast cancer, the most common cancer in women, needs improved drugs to increase patient survival. G4 cure aims to develop selective cancer drugs, that simultaneously affect two well-recognized cancer targets, the STAT3 protein and G-quadruplex DNA (G4) structures to reduce drug-resistance and improve treatment. Read more about G4 cancer cure in their onepager.
Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field. Read more about Hiloprobe in their onepager.
Are developing safe and resistance-breaking molecules that target an enzyme essential for nerve signaling in mosquitoes via a new mode of action. In contrast to current insecticides, we have designed our molecules to specifically target mosquitoes, without affecting other organisms. Read more about Insecticide case in their onepager.
GDPR and the patient data law, make sms and mail between caregivers and patients illegal. Instrube Health AB has designed an app, Memotus, tailor-made for caregivers to communicate with patients in a safe, easy, fast and legal way. With Memotus texts, pictures, videos and documents are sent safely. Identification is done via BankID. Read more about Memotus in their onepager.
Lipigon is a lipid biology specialist company. It utilizes proprietary and unique know-how and technologies to discover and develop novel therapies for patients with lipid disorders and other cardio-metabolic risk factors. Read more about Lipigon in their onepager.
Lipum is a biopharmaceutical company that has identified a novel target for the treatment of chronic inflammatory diseases. The lead candidate drug (SOL-116) is a fully-humanized monoclonal antibody directed towards the protein bile salt-stimulated lipase, BSSL. The anti-BSSL antibody is expected to have wide applicability for autoimmune and autoinflammatory diseases. Lipum has applied for an orphan drug designation (ODD) for the treatment of Juvenile Idiopathic Arthritis (JIA) as the first indication. Toxicological studies will be done during 2020 and clinical trials start during 2021. Read more about Lipum in their onepager.
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical needs such as prostate, lung, kidney, and endometrial cancer. Read more about MetaCurUm in their onepager.
Nordic Health Innovation
With the help of technology, we contribute to more accessible health care for those who need it most. We live by the motto “Empowering the patient”, which means that we want to put the patient in the driver’s seat when it comes to their own health and information that is collected about the individual, for example measurement data from health searches. Read more about Nordic Health Innovation in their onepager.
Omnio AB, is a biotechnical research and development company with the aim to develop pro-inflammatory protein based drug candidates based on the plasma protein plasminogen. Plasminogen occurs naturally in sufficient levels in the circulation of healthy people, and can thus be derived through blood plasma fractionation procedures, such as the Cohn Process or ProMetic’s PPPSTM process. Read more about Omnio in their onepager.
Pro Test Diagnostics
Pro Test Diagnostics is developing a routine test to monitor and detect illegal use of one’s own stored blood to enhance performance in elite athletes. The ABT™-test can expose athletes who have used blood doping and the result is not affected by the athlete’s training intensity, the use of high-altitude training or the use of low oxygen tents. Read more about Pro Test Diagnostics in their onepager.
Quretech Bio develops innovative antibiotics by stopping bacterial virulence with a first-in-class active substance. The approach is not to kill bacteria, but make them harmless – thus complementing existing treatments and making established antibiotic drugs more effective without causing resistance. Read more about Quretech Bio in their onepager.